BERKELEY, CA USA (UroToday) - In this presentation, Dr. Charles Ryan discusses quality-of-life results, demonstrating a more real-world view of how patients actually feel and function when receiving abiraterone acetate therapy.
The case lecture presentation will take approximately 20 minutes to complete.
Related Presentations:
- Treatment of chemotherapy-naive metastatic castration-resistant prostate cancer - Case Lecture Presentation
- Maximum androgen blockade with abiraterone - Case Lecture Presentation, by Charles J. Ryan, MD
Learn More About mCRPC Treatment
- Successful treatment of advanced metastatic prostate cancer following chemotherapy based on molecular profiling, "Beyond the Abstract," by Charles E. Myers, MD
- Advances in the treatment of prostate cancer - dawn of a new era - Abstract
- Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases - Abstract
- Non-metastatic CRPC and asymptomatic metastatic CRPC: Which treatment for which patient? - Abstract